Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The closing price of Monte Rosa Therapeutics Inc (NASDAQ: GLUE) was $15.99 for the day, down -0.19% from the previous closing price of $16.02. In other words, the price has decreased by -$0.19 from its previous closing price. On the day, 0.64 million shares were traded. GLUE stock price reached its highest trading level at $16.3 during the session, while it also had its lowest trading level at $15.86.
Ratios:
Our analysis of GLUE’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.66 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 7.18. For the most recent quarter (mrq), Quick Ratio is recorded 6.54 and its Current Ratio is at 6.54. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.15.
Upgrades & Downgrades
In the most recent recommendation for the company, Wells Fargo on December 19, 2024, Downgraded its rating to Equal Weight and sets its target price to $11 from $14 previously.
On February 15, 2024, Wedbush started tracking the stock assigning a Outperform rating and target price of $11.
Wells Fargo Upgraded its Equal Weight to Overweight on January 03, 2023, while the target price for the stock was maintained at $18.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jun 03 ’25 when Dunn Edmund sold 2,062 shares for $4.45 per share. The transaction valued at 9,174 led to the insider holds 23,732 shares of the business.
Leo Chandra P. bought 10,000 shares of GLUE for $58,383 on Mar 24 ’25. The Director now owns 10,000 shares after completing the transaction at $5.84 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GLUE now has a Market Capitalization of 1041232960 and an Enterprise Value of 690142976. As of this moment, Monte’s Price-to-Earnings (P/E) ratio for their current fiscal year is 52.36. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.74 while its Price-to-Book (P/B) ratio in mrq is 4.02. Its current Enterprise Value per Revenue stands at 3.802 whereas that against EBITDA is 40.982.
Stock Price History:
The Beta on a monthly basis for GLUE is 1.57, which has changed by 0.5434363 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, GLUE has reached a high of $16.66, while it has fallen to a 52-week low of $3.50. The 50-Day Moving Average of the stock is 47.65%, while the 200-Day Moving Average is calculated to be 146.75%.
Shares Statistics:
GLUE traded an average of 1.48M shares per day over the past three months and 951510 shares per day over the past ten days. A total of 61.79M shares are outstanding, with a floating share count of 42.21M. Insiders hold about 35.18% of the company’s shares, while institutions hold 70.67% stake in the company. Shares short for GLUE as of 1763078400 were 7396896 with a Short Ratio of 5.01, compared to 1760486400 on 8082854. Therefore, it implies a Short% of Shares Outstanding of 7396896 and a Short% of Float of 14.799999999999999.
Earnings Estimates
The dynamic stock of Monte Rosa Therapeutics Inc (GLUE) is currently being evaluated by a team of 7.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.47, with high estimates of -$0.37 and low estimates of -$0.53.
Analysts are recommending an EPS of between $0.04 and -$0.44 for the fiscal current year, implying an average EPS of -$0.2. EPS for the following year is -$1.42, with 7.0 analysts recommending between -$0.13 and -$2.03.
Revenue Estimates
A total of 7 analysts have provided revenue estimates for GLUE’s current fiscal year. The highest revenue estimate was $160.9M, while the lowest revenue estimate was $121M, resulting in an average revenue estimate of $136.47M. In the same quarter a year ago, actual revenue was $75.62M
